- Home
- CHNR vs BCDA Comparison
CHNR vs BCDA Comparison
Compare CHNR & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHNR
- BCDA
- Stock Information
- Founded
- CHNR N/A
- BCDA N/A
- Country
- CHNR Hong Kong
- BCDA United States
- Employees
- CHNR N/A
- BCDA N/A
- Industry
- CHNR Precious Metals
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- CHNR Basic Materials
- BCDA Health Care
- Exchange
- CHNR Nasdaq
- BCDA Nasdaq
- Market Cap
- CHNR 6.4M
- BCDA 7.9M
- IPO Year
- CHNR 1995
- BCDA N/A
- Fundamental
- Price
- CHNR $0.79
- BCDA $2.68
- Analyst Decision
- CHNR
- BCDA Strong Buy
- Analyst Count
- CHNR 0
- BCDA 1
- Target Price
- CHNR N/A
- BCDA $25.00
- AVG Volume (30 Days)
- CHNR 148.0K
- BCDA 73.1K
- Earning Date
- CHNR 01-01-0001
- BCDA 11-06-2024
- Dividend Yield
- CHNR N/A
- BCDA N/A
- EPS Growth
- CHNR N/A
- BCDA N/A
- EPS
- CHNR N/A
- BCDA N/A
- Revenue
- CHNR N/A
- BCDA $428,000.00
- Revenue This Year
- CHNR N/A
- BCDA $6.92
- Revenue Next Year
- CHNR N/A
- BCDA N/A
- P/E Ratio
- CHNR N/A
- BCDA N/A
- Revenue Growth
- CHNR N/A
- BCDA 0.71
- 52 Week Low
- CHNR $0.55
- BCDA $1.96
- 52 Week High
- CHNR $8.85
- BCDA $23.25
- Technical
- Relative Strength Index (RSI)
- CHNR 53.35
- BCDA 49.01
- Support Level
- CHNR $0.68
- BCDA $2.39
- Resistance Level
- CHNR $0.83
- BCDA $2.90
- Average True Range (ATR)
- CHNR 0.10
- BCDA 0.18
- MACD
- CHNR -0.00
- BCDA -0.00
- Stochastic Oscillator
- CHNR 24.60
- BCDA 53.70
About CHNR China Natural Resources Inc.
China Natural Resources Inc is an investment holding company. It principally engaged in the exploration and mining and wastewater treatment businesses in the People's Republic of China. The company has two operating segments: (i) Wastewater treatment segment, which consists of sales of assembled equipment, provision of construction service, and participation in PPP projects as an operator (ii) Exploration and mining segment, which consists of the exploration of lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and the trading of copper ores products. It earns the majority of its revenue from the Wastewater treatment segment.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).